Compare BIO-TECHNE Corp (TECH) vs Verisign, Inc. (VRSN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Verisign, Inc. — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Verisign, Inc. trades at $288.99 (market cap $26.52B). The key difference: Verisign, Inc. is far larger — about 2.4× BIO-TECHNE Corp's market cap, and Verisign, Inc. pays the higher dividend (1.1%). Which is the better fit depends on your goals.
| TECH | VRSN | |
|---|---|---|
Market Cap | $11.24B | $26.52B |
Sector | Health | Technology |
52-Week High | $72.29 | $310.00 |
52-Week Low | $43.31 | $211.49 |
Enterprise Value | $11.32B | $27.82B |
Dividend Yield | 0.44% | 1.1% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
VRSN trades at $294.56, up 0.69% today, with a bullish technical signal and strong support near $290. The company reported Q2 2026 revenue of $435 million, up 6% year-over-year, with EPS of $2.38 beating expectations. Analyst consensus is a Buy with a $320 price target, citing growth from AI-driven domain registrations and the recent .web domain delegation.
Outlook remains positive with double-digit profit growth potential from pending price hikes, though risks include contract renewals and high valuation multiples. The stock's current price offers an 8.6% upside to the consensus target, supported by stable cash flows and a dominant market position in domain registry services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Verisign, Inc.
Verisign is the sole authorized registry for several generic top-level domains, including the widely utilized .com and .net top-level domains. The company operates critical Internet infrastructure to support the domain name system, including operating two of the world's 13 root servers that are used to route Internet traffic. In 2018, the firm sold off its Security Services business, signalling a renewed focus on the core registry business.
Read more on VRSN →
